

# Cihan Ay

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8429729/publications.pdf>

Version: 2024-02-01

274  
papers

12,755  
citations

23567  
58  
h-index

31849  
101  
g-index

280  
all docs

280  
docs citations

280  
times ranked

11698  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction of venous thromboembolism in cancer patients. Blood, 2010, 116, 5377-5382.	1.4	643
2	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncology, The, 2019, 20, e566-e581.	10.7	458
3	American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Advances, 2021, 5, 927-974.	5.2	431
4	High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood, 2008, 112, 2703-2708.	1.4	366
5	Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1178-1191.	2.3	366
6	D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study. Journal of Clinical Oncology, 2009, 27, 4124-4129.	1.6	343
7	Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thrombosis and Haemostasis, 2017, 117, 219-230.	3.4	337
8	Venous thromboembolism in cancer patients: a population-based cohort study. Blood, 2021, 137, 1959-1969.	1.4	277
9	High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica, 2012, 97, 1158-1164.	3.5	269
10	Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. Journal of Thrombosis and Haemostasis, 2012, 10, 1363-1370.	3.8	228
11	A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematology, the, 2018, 5, e289-e298.	4.6	219
12	Biomarkers for prediction of venous thromboembolism in cancer. Blood, 2013, 122, 2011-2018.	1.4	208
13	Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients. Journal of Thrombosis and Haemostasis, 2018, 16, 508-518.	3.8	202
14	Prediction of Venous Thromboembolism in Patients With Cancer by Measuring Thrombin Generation: Results From the Vienna Cancer and Thrombosis Study. Journal of Clinical Oncology, 2011, 29, 2099-2103.	1.6	196
15	High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Journal of Thrombosis and Haemostasis, 2010, 8, 114-120.	3.8	195
16	Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH. Hamostaseologie, 2021, 41, 184-189.	1.9	189
17	Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants. Thrombosis Research, 2015, 136, 582-589.	1.7	187
18	Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. Blood, 2017, 129, 1831-1839.	1.4	164

#	ARTICLE	IF	CITATIONS
19	Biomarkers and Venous Thromboembolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 332-336.	2.4	143
20	Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2018, 16, 1246-1249.	3.8	140
21	High Factor VIII Levels Independently Predict Venous Thromboembolism in Cancer Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 2176-2181.	2.4	139
22	2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncology, The, 2022, 23, e334-e347.	10.7	138
23	Venous thromboembolism a manifestation of the metabolic syndrome. Haematologica, 2007, 92, 374-380.	3.5	137
24	Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood, 2021, 137, 1669-1678.	1.4	123
25	Neutrophils and neutrophil extracellular traps enhance venous thrombosis in mice bearing human pancreatic tumors. Haematologica, 2020, 105, 218-225.	3.5	117
26	Venous thrombosis and cancer: from mouse models to clinical trials. Journal of Thrombosis and Haemostasis, 2015, 13, 1372-1382.	3.8	112
27	High Concentrations of Soluble P-Selectin Are Associated with Risk of Venous Thromboembolism and the P-Selectin Thr715 Variant. Clinical Chemistry, 2007, 53, 1235-1243.	3.2	110
28	Tumor Grade Is Associated With Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study. Journal of Clinical Oncology, 2012, 30, 3870-3875.	1.6	110
29	The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2019, 17, 1772-1778.	3.8	107
30	Outpatient Pulmonary Rehabilitation in Patients with Long COVID Improves Exercise Capacity, Functional Status, Dyspnea, Fatigue, and Quality of Life. Respiration, 2022, 101, 593-601.	2.6	105
31	Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer. Haematologica, 2018, 103, 1549-1556.	3.5	95
32	Thrombin generation in morbid obesity: significant reduction after weight loss. Journal of Thrombosis and Haemostasis, 2010, 8, 759-765.	3.8	91
33	Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT). Journal of Thrombosis and Haemostasis, 2021, 19, 1819-1822.	3.8	91
34	Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. Thrombosis and Haemostasis, 2014, 111, 670-678.	3.4	88
35	Platelets in cancer and thrombosis. Hamostaseologie, 2014, 34, 54-62.	1.9	83
36	Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society. European Heart Journal, 2022, 43, 183-189.	2.2	83

#	ARTICLE	IF	CITATIONS
37	Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer. <i>British Journal of Haematology</i> , 2019, 186, 311-320.	2.5	82
38	Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants. <i>Annals of Oncology</i> , 2019, 30, 897-907.	1.2	80
39	Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting. <i>Thrombosis and Haemostasis</i> , 2016, 116, 651-658.	3.4	79
40	Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis, and thrombotic disease. <i>Journal of Experimental Medicine</i> , 2017, 214, 2121-2138.	8.5	78
41	Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 980-988.	3.7	78
42	Peripheral blood microvesicles secretion is influenced by storage time, temperature, and anticoagulants. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2016, 89, 663-672.	1.5	76
43	Tissue factor is induced by interleukin-33 in human endothelial cells: a new link between coagulation and inflammation. <i>Scientific Reports</i> , 2016, 6, 25171.	3.3	74
44	Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: Updated systematic review and meta-analysis of randomized controlled trials. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 550-561.	2.3	69
45	The "GGCC"™ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. <i>Leukemia</i> , 2009, 23, 1924-1926.	7.2	68
46	Circulating procoagulant microparticles in cancer patients. <i>Annals of Hematology</i> , 2011, 90, 447-453.	1.8	65
47	Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study. <i>Haematologica</i> , 2013, 98, 1309-1314.	3.5	65
48	Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality. <i>PLoS ONE</i> , 2014, 9, e111440.	2.5	64
49	Atrial fibrillation and cancer " An unexplored field in cardiovascular oncology. <i>Blood Reviews</i> , 2019, 35, 59-67.	5.7	64
50	Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. <i>Neuro-Oncology</i> , 2014, 16, 1645-1651.	1.2	63
51	Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS). <i>Thrombosis Research</i> , 2014, 133, S39-S43.	1.7	63
52	Increased mortality in patients with the lupus anticoagulant: the Vienna Lupus Anticoagulant and Thrombosis Study (LATS). <i>Blood</i> , 2015, 125, 3477-3483.	1.4	63
53	Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients. <i>Oncologist</i> , 2016, 21, 252-257.	3.7	63
54	Human pancreatic tumors grown in mice release tissue factor-positive microvesicles that increase venous clot size. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 2208-2217.	3.8	63

#	ARTICLE	IF	CITATIONS
55	Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer—a nationwide analysis. <i>European Heart Journal</i> , 2021, 42, 2299-2307.	2.2	62
56	Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients — results from the Vienna Cancer And Thrombosis Study (CATS). <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 17-22.	3.8	61
57	Anticoagulation of cancer patients with non-atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1247-1252.	3.8	60
58	Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features. <i>European Journal of Clinical Investigation</i> , 2013, 43, 277-285.	3.4	59
59	Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 390-397.	3.8	59
60	Venous thromboembolism in cancer patients — Risk scores and recent randomised controlled trials. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1042-1048.	3.4	58
61	Hypercoagulability, venous thromboembolism, and death in patients with cancer. <i>Thrombosis and Haemostasis</i> , 2016, 115, 817-826.	3.4	58
62	Low-density lipoprotein receptor-related protein 1 polymorphism 663 C>T affects clotting factor VIII activity and increases the risk of venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 497-502.	3.8	56
63	Occult cancer screening in patients with venous thromboembolism: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 2076-2079.	3.8	56
64	Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2018, 125, 1581-1589.	2.3	55
65	Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. <i>Thrombosis Research</i> , 2013, 131, 162-165.	1.7	53
66	Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 753-770.	1.0	53
67	Thrombosis risk and survival in cancer patients with elevated C-reactive protein. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 57-63.	3.8	52
68	Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 294-305.	3.8	52
69	Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna Investigation of Atrial Fibrillation and Thromboembolism in Patients on Hemodialysis (VIVALDI). <i>PLoS ONE</i> , 2017, 12, e0169400.	2.5	51
70	The impact of severe haemophilia on the social status and quality of life among Austrian haemophiliacs. <i>Haemophilia</i> , 2008, 14, 703-708.	2.1	50
71	Diagnostic and therapeutic approach in adult patients with traumatic brain injury receiving oral anticoagulant therapy: an Austrian interdisciplinary consensus statement. <i>Critical Care</i> , 2019, 23, 62.	5.8	50
72	Circulating procoagulant microparticles in patients with venous thromboembolism. <i>Thrombosis Research</i> , 2009, 123, 724-726.	1.7	49

#	ARTICLE	IF	CITATIONS
73	High proportion of patients with bleeding of unknown cause in persons with a mild-to-moderate bleeding tendency: Results from the Vienna Bleeding Biobank (VIBB). <i>Haemophilia</i> , 2018, 24, 405-413.	2.1	49
74	Association Between the Metabolic Syndrome, Its Individual Components, and Unprovoked Venous Thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 2478-2485.	2.4	48
75	Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 664-669.	2.3	47
76	Microparticle-associated tissue factor activity in patients with metastatic pancreatic cancer and its effect on fibrin clot formation. <i>Translational Research</i> , 2014, 163, 145-150.	5.0	46
77	The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1317-1321.	3.8	46
78	Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1121-1127.	3.8	45
79	Soluble p-selectin, D-dimer, and high-sensitivity C-reactive protein after acute deep vein thrombosis of the lower limb. <i>Journal of Vascular Surgery</i> , 2011, 54, 48S-55S.	1.1	44
80	Venous Thromboembolism in Brain Tumors: Risk Factors, Molecular Mechanisms, and Clinical Challenges. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 334-341.	2.7	44
81	Association of platelet activation markers with cancer-associated venous thromboembolism. <i>Platelets</i> , 2016, 27, 80-85.	2.3	42
82	The role of podoplanin in cancer-associated thrombosis. <i>Thrombosis Research</i> , 2018, 164, S34-S39.	1.7	42
83	Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 171-182.	1.2	42
84	Oral contraception and menstrual bleeding during treatment of venous thromboembolism: Expert opinion versus current practice. <i>Thrombosis Research</i> , 2017, 153, 101-107.	1.7	41
85	Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 446-455.	1.9	41
86	Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS). <i>Clinical Cancer Research</i> , 2016, 22, 200-206.	7.0	39
87	Association of Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio with the Risk of Thromboembolism and Mortality in Patients with Cancer. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1875-1884.	3.4	38
88	Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients. <i>Thrombosis Research</i> , 2012, 129, S6-S9.	1.7	36
89	IL-33 stimulates the release of procoagulant microvesicles from human monocytes and differentially increases tissue factor in human monocyte subsets. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1379-1390.	3.4	36
90	Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer. <i>Blood Advances</i> , 2021, 5, 487-495.	5.2	36

#	ARTICLE	IF	CITATIONS
91	Platelet-specific markers are associated with monocyte-platelet aggregate formation and thrombin generation potential in advanced atherosclerosis. <i>Thrombosis and Haemostasis</i> , 2016, 115, 615-621.	3.4	35
92	The role of ADAMTS-13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 503-514.	2.3	35
93	Factor XI Inhibitors for Prevention and Treatment of Venous Thromboembolism: A Review on the Rationale and Update on Current Evidence. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	2.4	35
94	Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban. <i>Annals of Hematology</i> , 2015, 94, 1463-1471.	1.8	34
95	Decreased platelet reactivity in patients with cancer is associated with high risk of venous thromboembolism and poor prognosis. <i>Thrombosis and Haemostasis</i> , 2017, 117, 90-98.	3.4	34
96	Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D-dimer analysis: A prospective study. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1348-1356.	3.8	34
97	Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients. <i>Clinical and Experimental Immunology</i> , 2014, 177, 253-260.	2.6	33
98	Thrombin-generating potential, plasma clot formation, and clot lysis are impaired in patients with bleeding of unknown cause. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1478-1488.	3.8	33
99	Determinants of factor VIII plasma levels in carriers of haemophilia A and in control women. <i>Haemophilia</i> , 2010, 16, 111-117.	2.1	32
100	Clinical implications of incidental venous thromboembolism in cancer patients. <i>European Respiratory Journal</i> , 2020, 55, 1901697.	6.7	31
101	Clinical significance of circulating microparticles for venous thrombo - embolism in cancer patients. <i>Hamostaseologie</i> , 2012, 32, 127-131.	1.9	30
102	Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art. <i>Frontiers in Cardiovascular Medicine</i> , 2015, 2, 30.	2.4	30
103	P-selectin gene haplotypes modulate soluble P-selectin concentrations and contribute to the risk of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2008, 99, 899-904.	3.4	29
104	Surgical treatment of the haemophilic pseudotumour: A single centre experience. <i>International Orthopaedics</i> , 2012, 36, 2157-2162.	1.9	29
105	Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: review of the literature on current practice and emerging options. <i>ESMO Open</i> , 2017, 2, e000188.	4.5	29
106	Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality. <i>Thrombosis Research</i> , 2014, 134, 44-49.	1.7	28
107	Clinical evidence for a link between microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia. <i>Thrombosis Research</i> , 2014, 133, 303-305.	1.7	28
108	Pulmonary embolism during the COVID-19 pandemic: Decline in diagnostic procedures and incidence at a university hospital. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 835-841.	2.3	28



#	ARTICLE	IF	CITATIONS
109	Oral anticoagulation with rivaroxaban during pregnancy: a case report. <i>Thrombosis and Haemostasis</i> , 2014, 112, 1323-1324.	3.4	27
110	Statins are Associated with Low Risk of Venous Thromboembolism in Patients with Cancer: A Prospective and Observational Cohort Study. <i>Thrombosis Research</i> , 2014, 134, 1008-1013.	1.7	27
111	Association of ABO blood group with bleeding severity in patients with bleeding of unknown cause. <i>Blood Advances</i> , 2020, 4, 5157-5164.	5.2	27
112	Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 297-303.	3.8	27
113	Tests predictive of thrombosis in cancer. <i>Thrombosis Research</i> , 2010, 125, S12-S15.	1.7	26
114	The role of fibrinogen plasma levels, the $\alpha$ 455G>A fibrinogen and the factor XIII A subunit (FXIII-A) Val34Leu polymorphism in cancer-associated venous thrombosis. <i>Thrombosis and Haemostasis</i> , 2011, 106, 908-913.	3.4	26
115	Outcome of Total Knee Arthroplasty in Hemophilic Arthropathy. <i>Journal of Arthroplasty</i> , 2014, 29, 749-752.	3.1	26
116	Alterations of blood coagulation in controlled human malaria infection. <i>Malaria Journal</i> , 2016, 15, 15.	2.3	26
117	Serum creatinine and albumin predict sarcoma-specific survival in patients with myofibroblastic and fibroblastic sarcomas. <i>Journal of Orthopaedic Research</i> , 2017, 35, 2815-2824.	2.3	26
118	Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: past, present and future. <i>Thrombosis Research</i> , 2020, 191, S3-S11.	1.7	26
119	Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. <i>Journal of Hepatology</i> , 2022, 76, 1090-1099.	3.7	26
120	Thrombin generation in type 2 diabetes with albuminuria and macrovascular disease. <i>European Journal of Clinical Investigation</i> , 2012, 42, 470-477.	3.4	25
121	Hemoglobin, alkaline phosphatase, and C-reactive protein predict the outcome in patients with liposarcoma. <i>Journal of Orthopaedic Research</i> , 2015, 33, 765-770.	2.3	25
122	Elevated serum creatinine and low albumin are associated with poor outcomes in patients with liposarcoma. <i>Journal of Orthopaedic Research</i> , 2016, 34, 533-538.	2.3	25
123	Association of complete blood count parameters, d-dimer, and soluble P-selectin with risk of arterial thromboembolism in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1335-1344.	3.8	25
124	Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study. <i>Thrombosis and Haemostasis</i> , 2022, 122, 646-656.	3.4	25
125	Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting. <i>Oncologist</i> , 2018, 23, 822-839.	3.7	24
126	The CHA2DS2-VASc score strongly correlates with glomerular filtration rate and predicts renal function decline over time in elderly patients with atrial fibrillation and chronic kidney disease. <i>International Journal of Cardiology</i> , 2018, 253, 71-77.	1.7	24



#	ARTICLE	IF	CITATIONS
127	Systemic Inflammation and Activation of Haemostasis Predict Poor Prognosis and Response to Chemotherapy in Patients with Advanced Lung Cancer. <i>Cancers</i> , 2020, 12, 1619.	3.7	24
128	The effect of resistance exercise on strength and safety outcome for people with haemophilia: A systematic review. <i>Haemophilia</i> , 2020, 26, 200-215.	2.1	23
129	Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk Score. <i>Thrombosis and Haemostasis</i> , 2022, 122, 818-829.	3.4	23
130	The angiotensin-converting enzyme insertion/deletion polymorphism and serum levels of angiotensin-converting enzyme in venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2007, 98, 777-782.	3.4	22
131	Epidemiology and risk factors for venous thromboembolism in lung cancer. <i>Current Opinion in Oncology</i> , 2016, 28, 145-149.	2.4	22
132	Procoagulant extracellular vesicles in amniotic fluid. <i>Translational Research</i> , 2017, 184, 12-20.e1.	5.0	22
133	The discriminatory power of bleeding assessment tools in adult patients with a mild to moderate bleeding tendency. <i>European Journal of Internal Medicine</i> , 2020, 78, 34-40.	2.2	22
134	Extended anticoagulation treatment for cancer-associated thrombosis Rates of recurrence and bleeding beyond 6 months: A systematic review. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 619-634.	3.8	22
135	Potent irreversible P2Y <sub>12</sub> inhibition does not reduce LPS-induced coagulation activation in a randomized, double-blind, placebo-controlled trial. <i>Clinical Science</i> , 2016, 130, 433-440.	4.3	21
136	Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation. <i>Clinical and Experimental Medicine</i> , 2018, 18, 325-336.	3.6	21
137	Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancer. <i>Thrombosis Research</i> , 2020, 187, 9-17.	1.7	21
138	The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. <i>Liver International</i> , 2020, 40, 1415-1426.	3.9	21
139	Natural IgM antibodies inhibit microvesicle-driven coagulation and thrombosis. <i>Blood</i> , 2021, 137, 1406-1415.	1.4	21
140	Platelet activation and function during eltrombopag treatment in immune thrombocytopenia. <i>Annals of Hematology</i> , 2012, 91, 109-113.	1.8	20
141	Presence of varicose veins in cancer patients increases the risk for occurrence of venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1993-2000.	3.8	20
142	Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant. <i>BMC Medicine</i> , 2017, 15, 54.	5.5	20
143	Establishing an online physical exercise program for people with hemophilia. <i>Wiener Klinische Wochenschrift</i> , 2019, 131, 558-566.	1.9	20
144	Exposure to vitamin k antagonists and kidney function decline in patients with atrial fibrillation and chronic kidney disease. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 207-216.	2.3	20

#	ARTICLE	IF	CITATIONS
145	The influence of thrombophilia on the long-term survival of patients with a history of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2013, 109, 79-84.	3.4	19
146	Atrial fibrillation in patients with end-stage renal disease on hemodialysis: Magnitude of the problem and new approach to oral anticoagulation. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 578-588.	2.3	19
147	How I treat cancer-associated thrombosis. <i>ESMO Open</i> , 2019, 4, e000610.	4.5	19
148	Outpatient Pulmonary Rehabilitation in Patients with Persisting Symptoms after Pulmonary Embolism. <i>Journal of Clinical Medicine</i> , 2020, 9, 1811.	2.4	19
149	Thrombin generation in patients with a bleeding tendency of unknown origin. <i>Annals of Hematology</i> , 2011, 90, 1099-1104.	1.8	18
150	Residual thrombin generation potential is inversely linked to the occurrence of atherothrombotic events in patients with peripheral arterial disease. <i>European Journal of Clinical Investigation</i> , 2014, 44, 319-324.	3.4	18
151	Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 254.	1.7	18
152	Management of Cancer-Associated Thrombosis: Unmet Needs and Future Perspectives. <i>TH Open</i> , 2021, 05, e376-e386.	1.4	18
153	Elevated levels of tissue factor pathway inhibitor in patients with mild to moderate bleeding tendency. <i>Blood Advances</i> , 2021, 5, 391-398.	5.2	18
154	Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry. <i>Viruses</i> , 2022, 14, 178.	3.3	18
155	High risk of adverse pregnancy outcomes in women with a persistent lupus anticoagulant. <i>Blood Advances</i> , 2019, 3, 769-776.	5.2	17
156	Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting. <i>Annals of Hematology</i> , 2020, 99, 2763-2771.	1.8	17
157	Altered platelet proteome in lupus anticoagulant (LA)-positive patients' protein disulfide isomerase and NETosis as new players in LA-related thrombosis. <i>Experimental and Molecular Medicine</i> , 2020, 52, 66-78.	7.7	17
158	Extracellular Vesicle-Associated Tissue Factor Activity in Prostate Cancer Patients with Disseminated Intravascular Coagulation. <i>Cancers</i> , 2021, 13, 1487.	3.7	17
159	Hemostatic Biomarkers and Venous Thromboembolism Are Associated With Mortality and Response to Chemotherapy in Patients With Pancreatic Cancer. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2837-2847.	2.4	17
160	ABO blood group type and risk of venous thromboembolism in patients with cancer. <i>Blood Advances</i> , 2022, 6, 6274-6281.	5.2	17
161	Risk of venous thromboembolism and primary prophylaxis in cancer. <i>Hamostaseologie</i> , 2012, 32, 132-137.	1.9	16
162	Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients. <i>Thrombosis Research</i> , 2015, 136, 865-869.	1.7	16

#	ARTICLE	IF	CITATIONS
163	A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability. <i>Clinical and Experimental Medicine</i> , 2017, 17, 251-256.	3.6	16
164	Venous thromboembolism and vascular access thrombosis in patients with end-stage renal disease on maintenance hemodialysis: Cross-sectional results of the Vienna Investigation of Atrial Fibrillation and thromboembolism in patients on hemodialysis (VIVALDI). <i>Thrombosis Research</i> , 2017, 158, 59-64.	1.7	16
165	Human milk triggers coagulation via tissue factor-exposing extracellular vesicles. <i>Blood Advances</i> , 2020, 4, 6274-6282.	5.2	16
166	Alterations of the Platelet Proteome in Lung Cancer: Accelerated F13A1 and ER Processing as New Actors in Hypercoagulability. <i>Cancers</i> , 2021, 13, 2260.	3.7	16
167	Microparticle-associated tissue factor activity in patients with acute unprovoked deep vein thrombosis and during the course of one year. <i>Thrombosis Research</i> , 2014, 134, 1093-1096.	1.7	15
168	Design and rationale of the non-interventional, edoxaban treatment in routine clinical practice in patients with venous Thromboembolism in Europe (ETNA-VTE-Europe) study. <i>Thrombosis Journal</i> , 2018, 16, 9.	2.1	15
169	Neutrophil subpopulations and their activation potential in patients with antiphospholipid syndrome and healthy individuals. <i>Rheumatology</i> , 2021, 60, 1687-1699.	1.9	15
170	Pain management in hemophilia: expert recommendations. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 1042-1056.	1.9	15
171	Long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia. <i>Thrombosis Research</i> , 2021, 207, 126-130.	1.7	15
172	Long-term survival of patients with a history of venous thromboembolism. <i>Annals of Hematology</i> , 2011, 90, 585-594.	1.8	14
173	Myeloid but not epithelial tissue factor exerts protective anti-inflammatory effects in acid aspiration-induced acute lung injury. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1625-1639.	3.8	14
174	Factor XI-deficient mice exhibit increased bleeding after injury to the saphenous vein. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1829-1833.	3.8	14
175	Prognostic Impact of Soluble P-Selectin on Long-Term Adverse Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention. <i>Thrombosis and Haemostasis</i> , 2019, 119, 340-347.	3.4	14
176	Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study. <i>Cancers</i> , 2020, 12, 2493.	3.7	14
177	Successful outcome in a pregnant woman with homozygous antithrombin deficiency. <i>Thrombosis and Haemostasis</i> , 2007, 98, 1377-1378.	3.4	14
178	Decrease in microvesicle-associated tissue factor activity in morbidly obese patients after bariatric surgery. <i>International Journal of Obesity</i> , 2016, 40, 768-772.	3.4	13
179	Low Systemic Levels of Chemokine C-C Motif Ligand 3 (CCL3) are Associated with a High Risk of Venous Thromboembolism in Patients with Glioma. <i>Cancers</i> , 2019, 11, 2020.	3.7	13
180	Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non-severe haemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1081-1086.	3.8	13

#	ARTICLE	IF	CITATIONS
181	Endogenous t-PA-antigen is an independent predictor of adverse cardiovascular events and all-cause death in patients with atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1069-1077.	3.8	12
182	Effect of combined treatment with immunoabsorption and membrane filtration on plasma coagulation—Results of a randomized controlled crossover study. <i>Journal of Clinical Apheresis</i> , 2016, 31, 29-37.	1.3	12
183	Detection of tissue factor-positive extracellular vesicles by laser scanning confocal microscopy. <i>Thrombosis Research</i> , 2017, 150, 65-72.	1.7	12
184	Screening for Occult Cancer in Patients with Venous Thromboembolism: Past, Present, and Future. <i>Hamostaseologie</i> , 2020, 40, 270-279.	1.9	12
185	Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer therapies. <i>Thrombosis Research</i> , 2022, 213, S58-S65.	1.7	12
186	Response to antiplatelet therapy is independent of endogenous thrombin generation potential. <i>Thrombosis Research</i> , 2013, 132, e24-e30.	1.7	11
187	Plasma clot properties in patients with a mild-to-moderate bleeding tendency of unknown cause. <i>Annals of Hematology</i> , 2015, 94, 1301-1310.	1.8	11
188	Platelets and hemophilia: A review of the literature. <i>Thrombosis Research</i> , 2017, 155, 131-139.	1.7	11
189	Tissue Factor: Catch Me If You Can!. <i>Journal of Clinical Oncology</i> , 2017, 35, 1128-1130.	1.6	11
190	Risk assessment models of cancer-associated thrombosis - Potentials and perspectives. <i>Thrombosis Update</i> , 2021, 5, 100075.	0.9	11
191	Unanswered questions in cancer-associated thrombosis. <i>British Journal of Haematology</i> , 2022, 198, 812-825.	2.5	11
192	Increased Citrullinated Histone H3 Levels in the Early Post-Resuscitative Period Are Associated with Poor Neurologic Function in Cardiac Arrest Survivors—A Prospective Observational Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 1568.	2.4	10
193	Growth differentiation factor-15 predicts major adverse cardiac events and all-cause mortality in patients with atrial fibrillation. <i>European Journal of Internal Medicine</i> , 2021, 88, 35-42.	2.2	10
194	Anticoagulation use and the risk of stroke and major bleeding in patients on hemodialysis: From the VIVALDI, a population-based prospective cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2984-2996.	3.8	10
195	The angiotensin-converting enzyme insertion/deletion polymorphism and serum levels of angiotensin-converting enzyme in venous thromboembolism. Data from a case control study. <i>Thrombosis and Haemostasis</i> , 2007, 98, 777-82.	3.4	10
196	OC-16 - Neutrophil extracellular traps and tissue factor-bearing microvesicles: a liaison dangereuse causing overt DIC in cancer patients?. <i>Thrombosis Research</i> , 2016, 140, S174-S175.	1.7	9
197	Impaired glucose metabolism is associated with increased thrombin generation potential in patients undergoing angioplasty and stenting. <i>Cardiovascular Diabetology</i> , 2018, 17, 131.	6.8	9
198	Clinical characteristics and 3-month outcomes in cancer patients with incidental <i>versus</i> clinically suspected and confirmed pulmonary embolism. <i>European Respiratory Journal</i> , 2021, 58, 2002723.	6.7	9

#	ARTICLE	IF	CITATIONS
199	Comparison of metal on metal versus polyethyleneâ€“ceramic bearing in uncemented total hip arthroplasty in patients with haemophilic arthropathy. International Orthopaedics, 2014, 38, 1369-1373.	1.9	8
200	Low extracellular vesicleâ€“associated tissue factor activity in patients with persistent lupus anticoagulant and a history of thrombosis. Annals of Hematology, 2019, 98, 313-319.	1.8	8
201	Antithrombotic agents for primary and secondary prevention of cardiovascular events in patients with end-stage renal disease on chronic hemodialysis. Atherosclerosis, 2020, 298, 1-6.	0.8	8
202	Emicizumab for the Treatment of Acquired Hemophilia_A: Lessons Learned from 4 Very Different Cases. Blood, 2018, 132, 2476-2476.	1.4	8
203	VTE risk assessment in cancer. PhlÃ©bologie, 2016, 45, 140-145.	0.3	8
204	Thrombomodulin in patients with mild to moderate bleeding tendency. Haemophilia, 2021, 27, 1028-1036.	2.1	8
205	Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors. Blood Advances, 2022, 6, 946-958.	5.2	8
206	Outcome of Cancer-Associated Venous Thromboembolism Is More Favorable among Patients with Hematologic Malignancies than in Those with Solid Tumors. Thrombosis and Haemostasis, 2022, 122, 1594-1602.	3.4	8
207	Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death. Translational Research, 2020, 215, 41-56.	5.0	7
208	How I Manage Cancer-Associated Thrombosis. Hamostaseologie, 2020, 40, 038-046.	1.9	7
209	Bleeding Risk Assessment in Patients with Venous Thromboembolism. Hamostaseologie, 2021, 41, 267-274.	1.9	7
210	Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites. Thrombosis and Haemostasis, 2022, 122, 353-362.	3.4	7
211	Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria. Scientific Reports, 2021, 11, 12967.	3.3	7
212	Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel. Thrombosis and Haemostasis, 2022, 122, 633-645.	3.4	7
213	Von Willebrand Factor and ADAMTS13 and long-term outcomes in patients undergoing percutaneous coronary intervention. Thrombosis Research, 2020, 196, 31-37.	1.7	6
214	Platelet activation and aggregation in different centrifugal-flow left ventricular assist devices. Platelets, 2022, 33, 249-256.	2.3	6
215	Challenging anticoagulation cases: Cancer-associated venous thromboembolism and chemotherapy-induced thrombocytopenia â€“ A case-based review of clinical management. Thrombosis Research, 2021, 199, 38-42.	1.7	6
216	Extracellular vesicles from amniotic fluid, milk, saliva, and urine expose complexes of tissue factor and activated factor VII. Journal of Thrombosis and Haemostasis, 2022, 20, 2306-2312.	3.8	6

#	ARTICLE	IF	CITATIONS
217	The VWF binding aptamer ronderaptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease. <i>Blood Advances</i> , 2022, 6, 5467-5476.	5.2	6
218	Function of platelets in apheresis platelet concentrates and in patient blood after transfusion as assessed by Impact®. <i>Transfusion</i> , 2010, 50, 1036-1042.	1.6	5
219	Combined effects of genetic polymorphisms of P-selectin and P-selectin glycoprotein ligand-1 on the binding of platelets to monocytes. <i>Thrombosis Research</i> , 2010, 125, 475-477.	1.7	5
220	The P-selectin gene Pro715 allele and low levels of soluble P-selectin are associated with reduced P2Y12 adenosine diphosphate receptor reactivity in clopidogrel-treated patients. <i>Atherosclerosis</i> , 2011, 217, 135-138.	0.8	5
221	Treatment and secondary prevention of venous thrombo-embolism in cancer patients. <i>Hamostaseologie</i> , 2012, 32, 139-144.	1.9	5
222	Association of Thrombin Generation Potential with Platelet PAR-1 Regulation and P-Selectin Expression in Patients on Dual Antiplatelet Therapy. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 126-132.	2.4	5
223	Symptoms, signs, suspicion and setting: aPESI score for cancer-associated pulmonary embolism?. <i>European Respiratory Journal</i> , 2017, 49, 1602225.	6.7	5
224	Longitudinal kidney function trajectories predict major bleeding, hospitalization and death in patients with atrial fibrillation and chronic kidney disease. <i>International Journal of Cardiology</i> , 2019, 282, 47-52.	1.7	5
225	ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries. <i>European Journal of Internal Medicine</i> , 2020, 82, 48-55.	2.2	5
226	ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3Âmonths. <i>Thrombosis Research</i> , 2020, 196, 297-304.	1.7	5
227	Risk assessment for recurrent venous thromboembolism in patients with cancer. <i>Thrombosis Update</i> , 2021, 5, 100080.	0.9	5
228	Association of elevated soluble P-selectin levels with fetal loss in women with a history of venous thromboembolism. <i>Thrombosis Research</i> , 2012, 129, 725-728.	1.7	4
229	Longitudinal analysis of extracellular vesicle-associated tissue factor activity in cancer patients. <i>Thrombosis Research</i> , 2020, 195, 215-218.	1.7	4
230	Fibrinolysis and bleeding of unknown cause. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12511.	2.3	4
231	Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma. <i>ESMO Open</i> , 2020, 5, e000647.	4.5	4
232	PO-01 - Congestive heart failure is an independent risk factor for venous thromboembolism and mortality in cancer patients. <i>Thrombosis Research</i> , 2016, 140, S176.	1.7	3
233	Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality. <i>Blood</i> , 2014, 124, 2859-2859.	1.4	3
234	Risk assessment and primary prevention of VTE in patients with cancer: Advances, challenges, and evidence gaps. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101347.	1.7	3

#	ARTICLE	IF	CITATIONS
235	The role of scientific publishing in the development of early career investigators. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 6-7.	2.3	2
236	First application of focused low-energy extracorporeal shockwave therapy in a patient with severe hemophilia A and plantar fasciitis. Wiener Klinische Wochenschrift, 2021, 133, 245-246.	1.9	2
237	Citrullinated Histone H3, a Biomarker for Neutrophil Extracellular Trap Formation, Predicts the Risk of Mortality in Patients with Cancer. Hamostaseologie, 2019, 39, .	1.9	2
238	Predictive Value of D-Dimer Levels for Venous Thromboembolism in Cancer Patients: Results from the Vienna Cancer and Thrombosis Study (CATS). Blood, 2008, 112, 3824-3824.	1.4	2
239	Risk Factors in Cancer Patients. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2021, 76, 465-475.	0.6	2
240	Venous thromboembolism risk, prophylaxis and management in cancer patients with COVID-19: An unmet medical need. Thrombosis Update, 2022, 6, 100098.	0.9	2
241	The role of platelets in antiviral immunity. Obstetrics, Gynecology and Reproduction, 2022, 16, 204-212.	0.5	2
242	Characterisation of inflammatory response, coagulation, and radiological findings in Katayama fever: a report of three cases at the Medical University of Vienna, Austria. BMC Infectious Diseases, 2014, 14, 357.	2.9	1
243	Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review. Thrombosis Research, 2018, 164, S203-S204.	1.7	1
244	Peri-interventional Triple Therapy With Dabigatran Improves Vasomotion and Promotes Endothelialization in Porcine Coronary Stenting Model. Frontiers in Cardiovascular Medicine, 2021, 8, 690476.	2.4	1
245	Decreased ADAMTS13 Activity Levels in Patients with a Bleeding Tendency of Unknown Origin. Blood, 2011, 118, 1218-1218.	1.4	1
246	Circulatory microRNAs as potential biomarkers for major adverse cardiac events in patients with atrial fibrillation. European Heart Journal, 2021, 42, .	2.2	1
247	Intraperitoneal Activation of Blood Coagulation via Tissue Factor Exposing Extracellular Vesicles in Patients with Liver Disease and Ascites. Hamostaseologie, 2019, 39, .	1.9	1
248	The path of uncovering a prothrombotic thrombocytopenic syndrome after viral vector-based COVID-19 vaccination: Where there is much light, the shadow is deep. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12609.	2.3	1
249	Vaccine-induced immune thrombotic thrombocytopenia: definition, risks with different vaccines, and regulatory responses. Obstetrics, Gynecology and Reproduction, 2021, 15, 562-575.	0.5	1
250	Impact of ABO Blood Group Type on Risk of Venous Thromboembolism in Patients with Cancer. Blood, 2021, 138, 2119-2119.	1.4	1
251	Lupus anticoagulant test persistence over time and its associations with future thrombotic events. Blood Advances, 2022, .	5.2	1
252	Bleeding risk assessment in end-stage kidney disease: validation of existing risk scores and evaluation of a machine learning-based approach. Thrombosis and Haemostasis, 2022, 0, .	3.4	1



#	ARTICLE	IF	CITATIONS
253	Immunthrombozytopenie. Wiener Klinische Wochenschrift Education, 2009, 4, 153-163.	0.0	0
254	Response: P-selectin ready for the "News at Six" Blood, 2009, 113, 1860-1861.	1.4	0
255	Comment on Ferroni et al.: "Impact of chemotherapy on venous thromboembolism.: Comment to: Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study" HAEMATOL/2012/073338 and HAEMATOL/2013/092528. Haematologica. 2014, 99, e28-e29.	3.5	0
256	P14.97 High risk of venous thromboembolism in patients with brain metastases from non-small cell lung cancer. Neuro-Oncology, 2019, 21, iii91-iii91.	1.2	0
257	Heparins as cancer therapy: in theory, they should have worked. Lancet Haematology,the, 2020, 7, e703-e704.	4.6	0
258	Growth differentiation factor-15 predicts major cardiac adverse events and all-cause mortality in patients with atrial fibrillation. , 2021, 41, .		0
259	Anticoagulation for stroke prevention in patients with atrial fibrillation on hemodialysis is associated with net-clinical harm. Hamostaseologie, 2021, 41, .	1.9	0
260	Factors influencing bleeding severity in adult patients with primary immune thrombocytopenia. Hamostaseologie, 2021, 41, .	1.9	0
261	Increased soluble thrombomodulin influences fibrin clot formation in patients with mild to moderate bleeding tendency. Hamostaseologie, 2021, 41, .	1.9	0
262	New Inhibitors in the Ageing Population: A retrospective, observational, cohort study of new inhibitors in older people with haemophilia. Thrombosis and Haemostasis, 2021, , .	3.4	0
263	Long-Term Survival of Patients with a History of Venous Thromboembolism. Blood, 2010, 116, 3168-3168.	1.4	0
264	The Metabolic SYNDROME and the RISK of Venous Thrombosis: RESULTS of AN Individual LEVEL Patient Meta-ANALYSIS. Blood, 2010, 116, 3177-3177.	1.4	0
265	Thrombotic Events in Lupus Anticoagulant Positive Patients Prospectively Correlate with Clinical Risk Factors - the Vienna Lupus Anticoagulant and Thrombosis Study (LATS). Blood, 2015, 126, 652-652.	1.4	0
266	AB0590...A validation study of the pregnancy morbidity questionnaire(PMQ) in women with antiphospholipid antibodies and pregnancy morbidity. , 2018, , .		0
267	The Role of Neutrophil Extracellular Traps in Cancer-Associated Arterial Thrombosis. Blood, 2018, 132, 2508-2508.	1.4	0
268	Altered Protein Profiles in Platelets of Lupus Anticoagulant Positive Patients - New Players in LA-related Thrombosis?. , 2019, 39, .		0
269	Programmed Cell Death Ligand 1 and Venous Thromboembolism in Patients with Primary Brain Tumors. , 2019, 39, .		0
270	The impact of ABO blood type on VWF and factor VIII levels and the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.5	0

#	ARTICLE	IF	CITATIONS
271	Anticoagulation in Patients with Brain Metastases. , 2020, , 139-143.		0
272	Renal Function and Risk of Arterial Thrombotic Events in Patients Positive for Lupus Anticoagulant. Blood, 2021, 138, 290-290.	1.4	0
273	Association of ABO Blood Group with Bleeding Severity in Patients with Bleeding of Unknown Cause. Blood, 2020, 136, 16-18.	1.4	0
274	Biomarkers of Haemostasis and Occurrence of Venous Thromboembolism Are Associated with Disease Progression and Poor Prognosis in Patients with Pancreatic Cancer. Blood, 2020, 136, 7-8.	1.4	0